Cyclopharm (ASX:CYC) secured a purchase order from the National Institutes of Health and a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, according to a Thursday Australian bourse filing.
The company has installed its core radiopharmaceutical product, Technegas, at two sites within the St. Charles Health System, marking its first implementation in the Pacific Northwest, the filing said.
The company's shares jumped almost 4% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.